


We claim:

- 1 -

SUB
a1

A method-of-treating a living animal for inhibition of progression or alleviation of a condition which is alleviated by a 5HT₂ or neuronal nicotinic receptor antagonist, comprising the step of administering to the said living animal an amount of a 1-aminoalkylcyclohexane compound selected from the group consisting of those of the formula



wherein R* is $-(CH_2)_n-(CR^6R^7)_m-NR^8R^9$

wherein $n+m = 0, 1, \text{ or } 2$

wherein R¹ through R⁷ are independently selected from the group consisting of hydrogen and lower-alkyl (1-6C),

- 13 -

A method of Claim 3 wherein X is 4 or 5.

- 14 -

A method of Claim 1 wherein the condition treated or inhibited is selected from the group consisting of emesis, anxiety disorders, schizophrenia, drug and alcohol abuse disorders, depressive disorders, cognitive disorders, Alzheimer's disease, cerebella tremor, Parkinson's disease, Tourette's, pain, and appetite disorders.

- 15 -

A method of Claim 1 wherein the compound is selected from the group consisting of

1-Amino-1,3,3,5,5-pentamethylcyclohexane,
1-Amino-1-propyl-3,3,5,5-tetramethylcyclohexane,
1-Amino-1,3,3,5(trans)-tetramethylcyclohexane (axial amino group),
1-Amino-1,3,5,5-tetramethyl-3-ethylcyclohexane (mixture of diastereomers),
1-Amino-1,3,5-trimethylcyclohexane (mixture of diastereomers),
1-Amino-1,3-dimethyl-3-propylcyclohexane (mixture of diastereomers),
1-Amino-1,3 (trans),5 (trans)-trimethyl-3(cis)-propylcyclohexane,
1-Amino-1,3-dimethyl-3-ethylcyclohexane,
1-Amino-1,3,3-trimethylcyclohexane,
1-Amino-1,3 (trans)-dimethylcyclohexane,
1-Amino-1-methyl-3 (trans) propylcyclohexane,
1-Amino-1-methyl-3 (trans) ethylcyclohexane,
1-Amino-1,3,3-trimethyl-5 (cis) ethylcyclohexane,
1-Amino-1,3,3-trimethyl-5 (trans) ethylcyclohexane,

N-methyl-1-Amino-1,3,3,5,5-pentamethylcyclohexane,
1-Amino-1-methylcyclohexane,
N,N-dimethyl-1-amino-1,3,3,5,5-pentamethylcyclohexane,
1-Amino-1,5,5-trimethyl-3(cis)-isopropyl-cyclohexane,
1-Amino-1,5,5-trimethyl-3(trans)-isopropyl-cyclohexane,
1-Amino-1-methyl-3(cis)-ethyl-cyclohexane,
1-Amino-1-methyl-3(cis)-methyl-cyclohexane,
1-Amino-5,5-diethyl-1,3,3-trimethyl-cyclohexane, and
N-(1,3,3,5,5-pentamethylcyclohexyl) pyrrolidine,
and optical isomers, enantiomers, hydrates and
pharmaceutically-acceptable salts of any of the
foregoing.

- 16 -


A method of Claim 1 wherein the compound is adminis-
tered in the form of a pharmaceutical composition thereof
comprising the compound in combination with one or more
pharmaceutically-acceptable diluents, excipients, or
carriers.

- 17 -

A method of Claim 15 wherein the compound is
administered in the form of a pharmaceutical composition
thereof comprising the compound in combination with one
or more pharmaceutically-acceptable diluents, excipients,
or carriers.

- 18 -

Use of a 1-aminoalkylcyclohexane selected from the group consisting of those of the formula



wherein R* is $-(CH_2)_n-(CR^6R^7)_m-NR^8R^9$

wherein $n+m = 0, 1, \text{ or } 2$

wherein R¹ through R⁷ are independently selected from the group consisting of hydrogen and lower-alkyl (1-6C), wherein R⁸ and R⁹ are independently selected from the group consisting of hydrogen and lower-alkyl or together represent lower-alkylene $-(CH_2)_x-$ wherein x is 2 to 5, inclusive, and optical isomers, enantiomers, hydrates, and pharmaceutically-acceptable salts thereof, in the manufacture of a medicament to treat a living animal for inhibition of progression or alleviation of a condition which is alleviated by a 5HT₃ or neuronal nicotinic receptor antagonist.

- 19 -

Use of Claim 18 wherein at least R¹, R⁴, and R⁵ are lower-alkyl.

- 20 -

Use of Claim 19 wherein R¹ through R⁵ are methyl.

- 36 -

MERZ30/dln

1-Amino-1,5,5-trimethyl-3(trans)-isopropyl-cyclohexane,
1-Amino-1-methyl-3(cis)-ethyl-cyclohexane,
1-Amino-1-methyl-3(cis)-methyl-cyclohexane,
1-Amino-5,5-diethyl-1,3,3-trimethyl-cyclohexane, and
N-(1,3,3,5,5-pentamethylcyclohexyl) pyrrolidine,
and optical isomers, enantiomers, hydrates and
pharmaceutically-acceptable salts of any of the
foregoing.

- 24 -

Use of claim 18 wherein the condition treated or
inhibited is selected from the group consisting of
emesis, anxiety disorders, schizophrenia, drug and
alcohol abuse disorders, depressive disorders, cognitive
disorders, Alzheimer's disease, cerebella tremor,
Parkinson's disease, Tourette's, pain, and appetite
disorders.

099406-0600